We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App





LGC Clinical Diagnostics Demonstrates How Labs Can Enhance QC Efficiencies at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: Multichem is a class leading, third-party, test-consolidated QC product range (Photo courtesy of LGC)
Image: Multichem is a class leading, third-party, test-consolidated QC product range (Photo courtesy of LGC)

LGC Clinical Diagnostics (Middlesex, UK) is attending Medlab Middle East 2023 where it is demonstrating how laboratories can enhance their quality control (QC) efficiencies through automated processes with independent QC and QC data management.

Under LGC Clinical Diagnostics Group, the company’s booth at this year’s Medlab Middle East is representing the combined brands: Maine Standards, SeraCare, Technopath Clinical Diagnostics, and The Native Antigen Company. LGC is presenting its comprehensive portfolio of catalogue and custom-developed diagnostic quality solutions and component materials with representatives from each company available to answer all the questions of visitors at its booth.

At Medlab Middle East 2023, LGC is showcasing Technopath’s total QC solution, Multichem QC and IAMQC software that provide clinical laboratories with significant cost, handling and time savings, whilst delivering higher confidence in analytical testing methods. With an extensive list of analytes included in the Multichem range of QC products, choice and flexibility are guaranteed for all customers. The third party QC products include General Clinical Chemistry, Immunoproteins, Immunoassay, Cardiac, Urine Chemistry, Infectious Disease, Diabetes and other Esoteric controls. The controls are offered in assayed and unassayed formats. Technopath’s human based control matrix offers unrivalled test consolidation through increased control stability and diminished matrix effects. Together, these aspects of control manufacture offer greater control efficiencies without compromising compliance or confidence in patient results.

LGC is also demonstrating the IAMQC Software from Technopath that provides laboratory managers and technologists with a range of QC software tools to analyze their QC results in real-time. IAMQC Software tools allow users to automate, centralize, standardize and improve QC processes in a laboratory setting. A combination of modules satisfies the varying levels of QC requirements in individual laboratories and is easily tailored to meet different QC management expectations. This also includes the new IAMQC Infinity that incorporates all the functionality of IAMQC Peer, Daily and Expert in one application. The powerful cloud based software designed to exactly meet specific QC solution needs has a feature-based interface that allows the laboratory to build their custom solution and then to seamlessly add in further sophisticated features as and when needed.

Related Links:
LGC

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.